Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE LA 120 50 versus ORETICYL 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE LA 120 50 versus ORETICYL 25.
INDERIDE LA 120/50 vs ORETICYL 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propranolol is a nonselective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium reabsorption and promoting diuresis.
Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive NaCl cotransporter, increasing excretion of sodium, chloride, and water. Deserpidine depletes catecholamines from peripheral sympathetic nerve endings by binding to the vesicular monoamine transporter, reducing vascular resistance and heart rate.
One capsule orally once daily, containing 120 mg propranolol HCl and 50 mg hydrochlorothiazide.
Hydrochlorothiazide 25 mg orally once daily; may increase to 50 mg daily if needed.
None Documented
None Documented
Propranolol: 3-6 hours; Hydrochlorothiazide: 6-15 hours. Note: Inderide LA is an extended-release formulation; effective half-life extended to approximately 8-12 hours for propranolol component.
2.5 hours; in renal impairment may extend to 8–15 hours.
Primarily hepatic metabolism (90%+), with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for negligible amounts.
Primarily renal (95% unchanged); minimal biliary (<5%).
Category C
Category C
Beta-Blocker/Diuretic Combination
Diuretic Combination